Just before Christmas, COO Ejvind Mortz visited beautiful Stockholm in Sweden.
The purpose of the trip was to discuss the final details of our new collaboration with Affibody AB on analysis of Host Cell Protein (HCP) in biopharmaceuticals over the next 12 months.
Alphalyse recently finished a 3-year development project with University of Southern Denmark and Statens Serum Institute (Denmark). Together, we developed groundbreaking new HCP analysis methods based on LC-MS/MS technology.
We’re now further developing the technology by testing and validating HCP levels in biosimilars and biopharmaceuticals according to regulatory guidelines.
Affibody thus joins the project as one of our test customers, giving us the opportunity to provide them with detailed HCP analysis.